Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY
Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY
Aligos Therapeutics2024年第一季度GAAP每股收益美元（0.22美元）未達到預期（0.19美元），銷售額爲986.000萬美元，低於同比272.3萬美元
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 58.49 percent increase over losses of $(0.53) per share from the same period last year. The company reported $986.000 thousand in sales this quarter. This is a 63.79 percent decrease over sales of $2.723 million the same period last year.
Aligos Therapeutics（納斯達克股票代碼：ALGS）公佈的季度虧損爲每股0.22美元，比分析師普遍預期的0.19美元（0.19美元）低15.79％。這比去年同期每股虧損0.53美元（0.53）增長了58.49％。該公司報告本季度銷售額爲98.6萬美元。這比去年同期的272.3萬美元銷售額下降了63.79％。